Thermo Fisher Scientific Inc. priced a $1.5 billion senior notes offering.
The offering comprises $750 million of 3.200% senior notes due 2027, at an issue price of 99.263% of the principal amount, and $750 million of 4.100% senior notes due 2047, at an issue price of 98.825% of the principal amount.
Issuance of the notes is expected to close Aug. 14, subject to customary closing conditions. Interest will be paid on a semiannual basis.
The company plans to use net proceeds to help fund its acquisition of Patheon NV, including the repayment of Patheon's debt. The transaction is expected to close by the end of the third quarter, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Merrill Lynch Pierce Fenner & Smith Inc. are acting as joint book-running managers for the offering.